Natera dips 3.85% as litigation headlines and post-earnings repositioning weigh
Natera shares fell about 3.85% on March 27, 2026, in the absence of a fresh company announcement, with trading pressure tied to post-earnings repositioning and lingering concerns around prenatal-testing litigation headlines. The recent $8.25 million Panorama/Vasistera settlement process and a March claim deadline have kept attention on the women’s health business even as the company emphasizes oncology growth.
1) What’s driving Natera lower today
Natera (NTRA) traded lower on March 27, 2026 (down about 3.85% to roughly $188), and web checks did not surface a new same-day company press release or SEC filing that clearly explains the move. Instead, the slide appears consistent with a risk-off pullback and positioning after the company’s late-February results, with renewed investor attention on litigation-related headlines around its prenatal testing franchise.
2) Prenatal-testing settlement headlines remain in the tape
One overhang in March has been the consumer class-action settlement tied to Natera’s Panorama/Vasistera prenatal screening tests, with an $8.25 million settlement and a claim deadline that has circulated broadly online (claim deadline March 23, 2026; final approval hearing scheduled for April 23, 2026). While the dollar amount is not large for a company of Natera’s size, the recurring visibility can weigh on sentiment around its women’s health business and billing/reputation narratives at the margin.
3) Context: recent earnings and the setup into the next catalyst
Natera reported fourth-quarter and full-year 2025 results on February 26, 2026, which has left the stock trading in a more headline-sensitive range as investors reassess growth versus profitability and valuation. The next major scheduled catalyst is the next earnings release date tracked by market calendars at May 7, 2026, which can also encourage short-term de-risking when there is no new positive catalyst on the day.